Canavan disease, is an autosomal recessive disorder caused by decreased function of the enzyme aspartoacylase. The clinical symptoms include macrocephaly, hypotonia, developmental delay, seizures, optic atrophy and dystonia. We reported three patients with psychomotor developmental delay, hypotonia and macrocephaly, who was diagnosed as Canavan disease after the investigations.
Rady LP, Vargas T, Tyring SK, Matolon R. Novel missence mutation (Y231C) in a patient Canavan Disease. Am J Genet. 1999; 87: 273-5.
Gerald M, Fenichel MD. Aspartoacyilase Deficiency (Canavan Disease). Clinical Pediatric Neurology USA Third Edition. 1997; 141-2.
Matalon R, Michals K, Kaul R. Canavan Disease: Spongy degeneration to molecular analysis. J Pediatr. 1995; 127: 511-7.
Perlman SJ, Mar S. Leukodystrophies. Adv Exp Med Biol. 2012; 724:154-71.
Gordon N. Canavan disease: a review of recent developments. Europ J Pediatr Neurol. 2001; 5: 65-9. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol. 2005; 15: 2284-2303.
Matalon R. Canavan disease diagfnosis and molecular analysis. Genet Test. 1997; 1: 21-5.
Kaul R, Gao PG, Matalon R, Aloya M, Su Q, et al. Identification and expression of eight novel mutations among non-jewish patients with Canavan Disease. Am J Hum Genet. 1996; 59: 95-102.
Topçu M, Yalnızoğlu D, Saatci I, et al. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly. Turk J Pediatr. 2004; 46: 67-71.
Yazışma Adresi / Address for Correspondence: Dr. Faruk İncecik Çukurova Üniversitesi Tıp Fakültesi, Çocuk Nöroloji Bilim Dalı 01330 Balcalı-ADANA e-mail: fincecik@yahoo.com geliş tarihi/received :06.11.2012 kabul tarihi/accepted:26.12.2012
Canavan Hastalığı: 3 Olgu Sunumu
Year 2013,
Volume: 38 Issue: 3, 495 - 498, 01.09.2013
Canavan hastalığı, aspartoaçilaz enziminin yetersiz fonksiyon göstermesine bağlı olarak gelişen otozomal resesif bir hastalıktır. Makrosefali, hipotoni, gelişme geriliği, nöbetler, optik atrofi ve distoni gibi klinik bulgular eşlik edebilmektedir. Psikomotor gelişme geriliği, hipotoni ve makrosefalisi olan, yapılan tetkikleri sonucunda Canavan hastalığı tanısı alan 3 hastayı sunduk.
Rady LP, Vargas T, Tyring SK, Matolon R. Novel missence mutation (Y231C) in a patient Canavan Disease. Am J Genet. 1999; 87: 273-5.
Gerald M, Fenichel MD. Aspartoacyilase Deficiency (Canavan Disease). Clinical Pediatric Neurology USA Third Edition. 1997; 141-2.
Matalon R, Michals K, Kaul R. Canavan Disease: Spongy degeneration to molecular analysis. J Pediatr. 1995; 127: 511-7.
Perlman SJ, Mar S. Leukodystrophies. Adv Exp Med Biol. 2012; 724:154-71.
Gordon N. Canavan disease: a review of recent developments. Europ J Pediatr Neurol. 2001; 5: 65-9. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol. 2005; 15: 2284-2303.
Matalon R. Canavan disease diagfnosis and molecular analysis. Genet Test. 1997; 1: 21-5.
Kaul R, Gao PG, Matalon R, Aloya M, Su Q, et al. Identification and expression of eight novel mutations among non-jewish patients with Canavan Disease. Am J Hum Genet. 1996; 59: 95-102.
Topçu M, Yalnızoğlu D, Saatci I, et al. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly. Turk J Pediatr. 2004; 46: 67-71.
Yazışma Adresi / Address for Correspondence: Dr. Faruk İncecik Çukurova Üniversitesi Tıp Fakültesi, Çocuk Nöroloji Bilim Dalı 01330 Balcalı-ADANA e-mail: fincecik@yahoo.com geliş tarihi/received :06.11.2012 kabul tarihi/accepted:26.12.2012